Get started
Author

Mariana Vieira

Observed name: MARIANA VIEIRA
Institution: Bial (Portugal)
ORCID: 0009-0003-3644-894X
Observed ORCID: 0009-0003-3644-894X
OpenAlex ID: A5111088673
Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience
2017 · Helena Gama, Mariana Vieira, et al. · Drug Safety · 26
PDF
Cerebral Venous Air Embolism: A Rare Phenomenon
2019 · Antonio Costa Carneiro, Priscila Diaz, et al. · European Journal of Case Reports in Internal Medicine · 22
Eslicarbazepine acetate exposure in pregnant women with epilepsy
2018 · Raquel Costa, Luís M. Magalhães, et al. · Seizure · 18
PDF
Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
2021 · Luís M. Magalhães, Raquel Costa, et al. · Drug Safety · 10
PDF
Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy
2019 · Robert T. Wechsler, Rodney A. Radtke, et al. · Epilepsia · 9
PDF
Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective
2023 · Luís Guedes, Mariana Vieira, et al. · Epileptic Disorders · 8
PDF
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
2022 · Hamada Altalib, Todd Grinnell, et al. · Epilepsia Open · 4
Safety of opicapone after 5 years of post-marketing experience worldwide (P14-11.013)
2023 · Luis Guedes, Joana Graça, et al. · Neurology · 1
Analysis of Sodium Levels and Hyponatremia Events in Trials of Eslicarbazepine Acetate (ESL) in Pediatric Patients (Aged 4–17 years) (P5.268)
2018 · Inna Vaisleib, Michael Duchowny, et al. · Neurology · 1
Phase 1 Study to Investigate the Effect of P-glycoprotein Transporter Inhibition Mediated by Carvedilol on the Pharmacokinetics of Zamicastat
2021 · LUIS MAGALHAES, ANDREIA GUIMARAES, et al. · CHEST Journal
PDF
Ten years of post-marketing surveillance data of Eslicarbazepine acetate: reinforcement of the adult safety profile evidenced in clinical trials (4539)
2021 · Diogo Martins, Miguel Fonseca, et al. · Neurology
Psychiatric Adverse Events According to Psychiatric History and Current Status: A Post-hoc Analysis of Three Phase III Trials of Adjunctive Eslicarbazepine Acetate in Adults with Focal Seizures (4140)
2020 · Hamada Altalib, Todd Grinnell, et al. · Neurology
Analysis of Psychiatric Adverse Events and Suicidality in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures (P1.5-020)
2019 · Jay Salpekar, Mark Mintz, et al. · Neurology
Relationship Between Adverse Event Incidence and Eslicarbazepine Acetate (ESL) Dose Across Weight Groups in Clinical Trials of Adjunctive ESL in Children (Aged 4–17 Years) with Focal Seizures (P3.5-013)
2019 · Jesus E. Pina-Garza, Steven M. Wolf, et al. · Neurology
Analysis of Changes in Plasma Sodium Levels and Related Treatment-Emergent Adverse Events During Short- and Long-Term Use of Eslicarbazepine Acetate as Adjunctive and Monotherapy (P4.105)
2017 · Robert Wechsler, Rodney Radtke, et al. · Neurology
Works count: 15
Citation count: 99
H-index: 6
I10-index: 4
Year
Topic
Type